SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for AQST.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 73.11M
March 31, 2026 71.75M
December 31, 2025 79.85M
September 30, 2025 63.04M
June 30, 2025 59.91M
March 31, 2025 58.56M
December 31, 2024 50.18M
September 30, 2024 43.72M
June 30, 2024 38.98M
March 31, 2024 34.98M
December 31, 2023 31.75M
September 30, 2023 34.01M
June 30, 2023 39.09M
March 31, 2023 47.31M
December 31, 2022 52.88M
September 30, 2022 56.05M
June 30, 2022 55.72M
March 31, 2022 53.26M
December 31, 2021 53.48M
Date Value
September 30, 2021 54.08M
June 30, 2021 53.75M
March 31, 2021 54.51M
December 31, 2020 55.89M
September 30, 2020 56.78M
June 30, 2020 58.70M
March 31, 2020 61.05M
December 31, 2019 64.34M
September 30, 2019 66.57M
June 30, 2019 65.20M
March 31, 2019 82.60M
December 31, 2018 72.26M
September 30, 2018 61.13M
June 30, 2018 54.94M
March 31, 2018 21.30M
December 31, 2017 19.85M
September 30, 2017 12.29M
June 30, 2017 6.128M
March 31, 2017 6.128M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
LENZ Therapeutics, Inc. 151.57M
ANI Pharmaceuticals, Inc. 324.76M
Corcept Therapeutics, Inc. 556.47M
Veru, Inc. 16.05M
Johnson & Johnson 25.14B